VIDEO : Biotech challenged by financial crisis

Sujet : les IPOs et les biotechs vues par Soren Carlsen
Søren Carlsen (Managing Partner, Novo Ventures, Novo A/S) was born in 1952. Søren joined Novo Nordisk A/S as a research scientist in 1979. He was appointed Vice President of Biotechnology in 1986. In 1991 Søren moved to Davis, California, to establish Novozymes Biotech, Inc., which is a research based company focusing on the development of bioindustrial products. In 1994 Søren was appointed head of Novo Nordisk's Enzyme Business as Corporate Vice President and Chief Science Officer. In this function he headed 400 scientists in Denmark, USA, Japan and China.

In spring 2000 Søren moved to his present position at Novo A/S to establish Novo’s new investment activities. He serves on the boards of 7TM Pharma A/S, Santaris Pharma A/S and PTC Therapeutics, Inc., and is former director of Arpida Ltd.

Søren is chairman of the Association of Biotechnology Industries in Denmark. He was granted the Danish Chemistry Prize in 1988.